In a closely watched medical device patent dispute, Tenjin LLC and Parcus Medical LLC reached a full settlement on February 24, 2024, concluding litigation that had been filed in the Middle District of Florida in December 2022. The case centered on three U.S. patents—US9717587B2, US11504224B2, and US9999496B2—covering implant placement systems and one-handed tissue fixation methods, technologies that sit at the intersection of orthopedic surgery and soft tissue repair. The parties resolved their dispute in person at a mediation session in Tampa, with the court formally dismissing the case on February 27, 2024.

This settlement carries significant implications for IP stakeholders in the orthopedic and surgical fixation device space. For patent attorneys and in-house IP teams, the case illustrates how overlapping patent families covering procedural methods and implant constructions can generate complex infringement exposure. R&D leaders at medtech companies developing competing tissue fixation platforms should assess their freedom-to-operate positions against Tenjin’s patent portfolio, as the surviving, unsettled terms of the agreement remain confidential.

Aperçu du dossier

Les parties

Les brevets en cause

The three patents at issue—US9717587B2, US11504224B2, and US9999496B2—cover surgical systems and methods for placing implants and fixing soft tissue during orthopedic procedures, including innovations enabling one-handed operation by the surgeon. The patents protect specific implant constructions, insertion tools, and procedural workflows designed to streamline tissue attachment in procedures such as labral repair or ligament reconstruction. Real-world applications include arthroscopic shoulder, knee, and hip surgeries where precise, efficient anchor placement is critical to patient outcomes.

• • US9717587B2
• • US11504224B2
• • US9999496B2

Représentation juridique

Plaintiff Counsel: Goldasich, Vick & Fulk; Pennington PA (lead: Ben Allen Andrews)
Defendant Counsel: Calfee Halter & Griswold LLP; Shutts & Bowen LLP (lead: Brian Joshua Paul)

Chronologie du litige et historique de la procédure

The case was filed on December 15, 2022, in the U.S. District Court for the Middle District of Florida, a venue known for managing a steady docket of patent disputes in the life sciences and medical device sectors. As a first-instance district court proceeding, the case would have been subject to standard Federal Rules of Civil Procedure for patent litigation, including Markman claim construction proceedings, discovery, and potential trial before Judge Virginia M. Hernandez Covington.

The litigation spanned 439 days before closing on February 27, 2024—a duration consistent with a case that proceeded through initial pleadings, discovery, and at least one prior mediation attempt before reaching final resolution at a second in-person mediation session. The case was terminated on the basis of settlement, with the court’s dismissal order initially entered without prejudice, subject to conversion to a dismissal with prejudice after 60 days absent further court filing. No trial was held and no claim construction ruling was issued publicly, indicating the parties opted for a negotiated resolution rather than litigating to judgment.

Le verdict et l'analyse juridique

Résultat

The case concluded with a full settlement reached at a second in-person mediation held on February 24, 2024, at the Tampa offices of Shutts & Bowen LLP. Judge Virginia M. Hernandez Covington formally dismissed the action on February 27, 2024, initially without prejudice and subject to conversion to a dismissal with prejudice after 60 days. No damages award, royalty determination, or injunction was publicly entered, and the financial terms of the settlement remain confidential.

Analyse des causes du verdict

The case proceeded as a patent infringement action, and the following factors shaped its trajectory toward settlement:

• Tenjin LLC asserted three issued U.S. utility patents covering distinct but related aspects of surgical implant placement systems and one-handed tissue fixation methods, creating a layered infringement exposure for Parcus Medical’s product lines.
• The involvement of multiple implant constructions and fixation method products as accused instrumentalities broadened the scope of potential liability and complicated the cost-benefit calculus for continued litigation.
• A first mediation attempt preceded the final February 2024 session, indicating that settlement discussions were ongoing but required multiple rounds of negotiation before reaching resolution, suggesting substantive disagreement over valuation or license terms.
• The court’s dismissal order explicitly noted the limits of its jurisdiction post-settlement, advising parties that failure to perform settlement obligations must be pursued through a separate breach of contract action rather than reopening this case.

Signification juridique

1. 1. The court’s explicit guidance that incomplete performance of an executed settlement agreement—such as failure to disburse funds—does not constitute ‘good cause’ to reopen the action establishes a clear procedural boundary that practitioners in the Middle District of Florida should incorporate into settlement agreement drafting.
2. 2. With no Markman ruling or claim construction order entered before settlement, the scope of the three asserted patents remains judicially untested, preserving Tenjin’s ability to assert the same claims against other defendants without adverse narrowing constructions on record.
3. 3. The multi-patent assertion strategy involving overlapping utility patents directed at both device constructions and procedural methods reflects a portfolio enforcement approach that strengthens plaintiff leverage in medtech patent disputes and warrants attention from competitors in the orthopedic fixation space.

Points stratégiques à retenir

Pour les avocats spécialisés en brevets :

• Draft post-settlement dismissal stipulations in the Middle District of Florida with explicit performance milestones and agreed timelines, given the court’s refusal to retain jurisdiction over settlement performance and its strict ‘good cause’ standard for reopening.
• When asserting or defending against multi-patent portfolios in medtech, evaluate each patent’s claim scope independently during early case assessment to identify the strongest invalidity or non-infringement arguments before the first mediation session.
• The absence of a Markman ruling means Tenjin’s patent claims in US9717587B2, US11504224B2, and US9999496B2 carry no adverse judicial construction—counsel for future defendants should budget for full claim construction litigation rather than assuming favorable prior rulings.
• The two-law-firm structure on the defense side (Calfee Halter & Griswold LLP and Shutts & Bowen LLP) suggests a coordinated national/local counsel strategy that medtech defendants should consider when litigating in Florida federal courts with complex patent portfolios.

Pour les professionnels de la propriété intellectuelle :

• Monitor Tenjin LLC’s patent portfolio for continuation filings or new assertions arising from the same patent families, as the confidential settlement does not prevent re-assertion against third parties and the claims remain judicially unconstrued.
• Map your company’s tissue fixation and implant placement product portfolio against all three Tenjin patents—US9717587B2, US11504224B2, and US9999496B2—to identify any design or method overlap before regulatory clearance or commercial launch.

Pour les équipes de R&D :

• Engineering teams developing one-handed or assisted implant insertion tools should conduct FTO analysis specifically against Tenjin’s method claims, as process-based patent infringement can occur even when device structures differ materially from the patented embodiments.
• Design-around opportunities may exist in implant construction geometry and insertion mechanism actuation sequences; document R&D decisions and prior art searches contemporaneously to support future invalidity or non-infringement positions if litigation arises.